140 related articles for article (PubMed ID: 25936311)
1. Effects of different lipoprotein apheresis methods on serum protein levels.
Julius U; Siegert G; Kostka H; Schatz U; Hohenstein B
Atheroscler Suppl; 2015 May; 18():95-102. PubMed ID: 25936311
[TBL] [Abstract][Full Text] [Related]
2. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
[TBL] [Abstract][Full Text] [Related]
4. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
5. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
6. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
Bosch T; Lennertz A; Schenzle D; Dräger J;
J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
[TBL] [Abstract][Full Text] [Related]
7. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
8. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients.
Bramlage CP; Armstrong VW; Zapf A; Bramlage P; Mueller GA; Koziolek MJ
Ther Apher Dial; 2010 Apr; 14(2):136-42. PubMed ID: 20438534
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
11. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
[TBL] [Abstract][Full Text] [Related]
12. How to optimize lipoprotein apheresis treatment--a second look.
Schettler V; Neumann CL; Hagenah GC; Schulz EG; Wieland E
Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
[TBL] [Abstract][Full Text] [Related]
13. Why an apheresis center should offer more than one lipoprotein apheresis method.
Julius U; Fischer S; Schatz U; Passauer J; Bornstein S
Ther Apher Dial; 2013 Apr; 17(2):179-84. PubMed ID: 23551674
[TBL] [Abstract][Full Text] [Related]
14. One year experience with a low density lipoprotein apheresis system.
Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
[TBL] [Abstract][Full Text] [Related]
15. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Julius U; Metzler W; Pietzsch J; Fassbender T; Klingel R
Int J Artif Organs; 2002 Dec; 25(12):1180-8. PubMed ID: 12518963
[TBL] [Abstract][Full Text] [Related]
17. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lipid reduction with DALI and MONET.
Ramlow W; Röseler E; Heigl F; Spitthöver R; Ringel J; Schmitz G; Heinzler R; Abdul-Rahman N; Leistikow F; Himmelsbach F; Schettler V; Pham J; Kozik-Jaromin J
Atheroscler Suppl; 2017 Nov; 30():217-224. PubMed ID: 29096841
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis influences monocyte subpopulations.
Jellinghaus S; Reich C; Schatz U; Tselmin S; Ibrahim K; Pfluecke C; Schauer A; Bornstein SR; Hohenstein B; Strasser RH; Julius U; Poitz DM
Atheroscler Suppl; 2017 Nov; 30():108-114. PubMed ID: 29096825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]